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Sudden cardiac death (SCD) is an important cause of mortality worldwide. Although SCD is
most often associated with coronary heart disease, the risk of SCD in patients without
ischemic heart disease is well-established. Nonischemic cardiomyopathies, including
idiopathic dilated cardiomyopathy, hypertrophic cardiomyopathy and arrhythmogenic
right ventricular cardiomyopathy represent three unique disease entities that have been
shown to be highly associated with SCD and ventricular arrhythmias. A variety of risk
stratification tools have been investigated, although the optimal strategy remains unknown.
Identification of the arrhythmogenic substrate and treatment of ventricular arrhythmias in
these subgroups can be challenging. Herein, we aim to discuss the current understanding of
the anatomic and electrophysiologic substrate underlying ventricular arrhythmias and
highlight features that may be associated with a higher risk of SCD in these 3 conditions.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
Sudden cardiac death (SCD) is a term used to signify an abrupt
and unexpected cessation of cardiac activity leading to com-
plete hemodynamic collapse and resulting in the death of the
victim.1 Autopsy and clinical studies have shown that the
presence of structural heart disease increases the risk of SCD,
with coronary heart disease accounting for the majority of
cases. In up to 20% of cases, coronary artery disease is absent
and either non-ischemic cardiomyopathies or primary elec-
trical disorders (channelopathies) are implicated as the caus-
ative factor.2 However, in at least 5% of patients presenting
with SCD, a cardiac abnormality remains undetected.3versity of Pennsylvania,
7; fax: þ1 215 615 4350.
.edu (S. Dixit).
2013, Cardiological SocietAlthough it is difficult to consistently determine the inciting
rhythm for many out-of-hospital arrests, some studies have
reported ventricular tachyarrhythmias in up to 80% of these
patients.4,5 In contrast, studies of in-hospital arrest suggest
that as many as 80% of these events are asystole or PEA and
only 20% are VT/VF.6 Despite these data, the true prevalence
of SCD remains unknown. The estimates range from 180,000
to 450,000 cases annually, accounting for approximately
5e20% of the total annual mortality in the United States and
other industrialized nations.7e9 Interestingly, despite the
advances in the management of cardiovascular disease, the
overall prevalence of SCD has remained largely unchanged.
There have been long-standing efforts to treat those who
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death. Early attempts involved the use of anti-arrhythmic
drugs to reduce arrhythmic death post-myocardial infarction
but this was abandoned due to higher mortality associated
with these agents.10 The advent of implantable cardioverter-
defibrillators (ICDs) enabled prompt recognition and termi-
nation of ventricular tachyarrhythmias, including sustained
monomorphic ventricular tachycardia and ventricular fibril-
lation (VT/VF), leading to a demonstrable survival benefit in
both ischemic and non-ischemic cardiomyopathy (NICM) for
primary and secondary prevention of SCD.1116 Although ICD
therapy has been reproducibly shown to improve mortality in
eligible patients, the costs associated with this therapy war-
rant that it is used appropriately. To that end, a wide variety of
noninvasive techniques for risk stratification are available,
including LV ejection fraction assessment by echocardiogra-
phy, QRS duration estimates by surface 12-lead ECG, QT
interval/dispersion and heart rate variability, among others.17
More recently, cardiac magnetic resonance imaging (CMRI)
has been put forth as a highly sensitive and specific non-
invasive diagnostic modality for delineating myocardial scar
in the setting of NICM.18,19 Invasive electrophysiologic study
and/or intracardiac catheter mapping also offer an alternate
means of identifying and characterizing arrhythmogenic
substrate, although the prognostic value of programmed
stimulation remains unclear. Despite the plethora of available
options, there is a paucity of randomized clinical trials and a
lack of consensus in support of any one diagnostic algorithm
that can consistently stratify the risk for sudden cardiac
death.
In this review, we aim to discuss the anatomic and elec-
trophysiologic substrate for ventricular tachyarrhythmias
leading to SCD in patients with a NICM. We will focus pri-
marily on idiopathic dilated cardiomyopathy (IDCM) with
additional sections on hypertrophic cardiomyopathy (HCM)
and arrhythmogenic right ventricular cardiomyopathy
(ARVC). Our goals are to illuminate clinical features that may
be associated with a higher risk of SCD and to provide
commentary on challenging electrophysiologic features in
these scenarios that may have implications for further risk
stratification.2. Idiopathic dilated cardiomyopathy (IDCM)
2.1. Background
IDCM is a termused to represent both genetic and non-genetic
disorders characterized by impaired ventricular systolic
function and enlargement of the ventricular cavity size in the
absence of obstructive coronary artery disease or prior
myocardial infarction as well as other well known causes of
cardiac dysfunction such as valvular and hypertensive heart
disease.20 Its prevalence is estimated to be 1:2500 with up to
35% considered familial in origin and the remainder occurring
secondary to infection, toxins, autoimmune, neuromuscular
and nutritional disorders.8,20 Some studies estimate that 50%
of cardiomyopathy cases arewithout an identifiable cause and
are therefore labeled “idiopathic”.21 Non-sustained ventricu-
lar arrhythmias and ventricular premature depolarizations(VPDs) are common in this patient population but sustained
VT is less frequent, reported in only 5%.22e24 However, it is
possible that these estimates are flawed and the prevalence of
sustained VT may be higher. In landmark primary prevention
ICD trials, rates of appropriate ICD therapy for sustained VT/
VF have ranged from 18 to 31% in this population.16,25,26
2.2. Anatomic and electrophysiologic substrate
Limited data from small necropsy series of patients with
IDCM reveal both areas of grossly visible scar and regions of
irregular/patchy fibrosis intertwined with surviving
myocytes.27e29 These studies helped to shape our initial un-
derstanding of the VT substrate in IDCM, which has been
further enhanced by cardiac MRI studies. Initially developed
to detect necrosis caused by myocardial infarction, cardiac
MRI has shown distinct scar patterns in patients with
NICM.30,31 It is now well accepted that the arrhythmogenic
substrate in NICM is characterized by patchy, layered fibrosis
and irregular myocyte disarray usually in a perivalvular dis-
tribution with a propensity for the mid-myocardial and
epicardial layers.29
Catheter-based substrate mapping and ablation of ventric-
ulararrhythmias inNICMwasmodeledafter the techniqueused
in ICM.32,33 Ina seminal paperbyMarchlinski etal, initial voltage
criteria for normal and abnormal tissue were established and a
linear ablation strategy for interrupting the VT circuit was pro-
posed. The electroanatomic substrate abnormalities were
commonly found in the basal-lateral/perivalvular region with
an unusual predilection for the mid-myocardial and epicardial
layers (Fig. 1).34e36 Early observations during percutaneous
epicardial electroanatomicmapping showed the presence of fat
in the perivalvular region could mimic scar and thus more
specific signal criteria were established to distinguish the
two.37,38 It is important to note that the interventricular septum
can also harbor the substrate for VT in IDCMandmaybemissed
by routine catheter mapping due to a rim of healthy adjacent
tissue (Fig. 2).39 Recently, our group has demonstrated that
delayed conduction across the interventricular septummay be
an additional method for identifying intramural substrate
abnormalities.40
The importance of the routine surface 12-lead ECG in
deciphering the underlying arrhythmogenic substrate should
be emphasized. The ECG markers of delayed activation may
be subtle in patients with IDCM. Nevertheless, research by our
group has shown that basic QRS measurements during sinus
rhythm may help identify patients with IDCM manifesting
basal-lateral VT substrate.41 A simple three-step algorithm
(including lateral lead QRS fragmentation, absence of inferior
Q waves, and lead V6 S wave to R wave ratio) may also be
useful for distinguishing the presence of nonischemic from
ischemic VT substrate in a similar distribution.42
2.3. High-risk features
Risk stratification of SCD often includes an assessment of 1)
myocardial substrate 2) repolarization abnormalities and 3)
the autonomic nervous system (Table 1). In terms of
myocardial substrate abnormalities, reduced LV ejection
fraction has been repeatedly shown to be the most robust
Fig. 1 e Representative 3-dimensional electroanatomicmaps from three patients with IDCMwho underwent VT ablation. LV
endocardial and epicardial voltage maps are displayed in the posterior-anterior projection, using the typical color spectrum
to represent tissue voltage characteristics (red indicates scar and purple indicates healthy tissue). Two types of signals are
displayed in which “bipolar” reflects a narrower field of view and “unipolar”, which encompasses tissue characteristics
further from the catheter tip. Patient A: low endocardial and epicardial voltage is present in the perivalvular region
consistent with transmural scar. Patient B: normal endocardial and epicardial bipolar voltage but abnormal unipolar
voltage, suggestive of isolated mid-myocardial scar. Patient C: normal endocardial voltage but patchy scar in the basal-
lateral epicardium extending to the midwall. LV [ left ventricle; PA [ posterior-anterior projection; mV [ millivolt.
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helpful including subtleties such as intra-ventricular con-
duction delays, QRS notching and presence of early repolari-
zation abnormalities. QRS fragmentation has been shown to
be an independent risk factor formortality, andmay represent
an epsilon wave equivalent in patients with IDCM.43 Unlike
other scenarios, in patients with IDCM, signal-averaged ECG
has not been found to be consistently useful as a prognosti-
cating tool for SCD.44 Although echocardiography is the most
widely used modality for assessing cardiac function, in our
experience CMRI is more helpful for characterizing structural
abnormalities. Others have found this modality useful for
prognostication.18,19 With respect to repolarization abnor-
malities, QT dispersion, T-wave alternans and early repolari-
zation on the surface ECG have been reported as potential risk
factors for SCD; however, the relationship between these
markers and susceptibility to tachyarrhythmias is not clearly
established.17 Lastly, markers of dysautonomias, which
include decreased HR variability, abnormal heart rate recov-
ery on stress testing and baroreceptor sensitivity, are also
occasionally used clinically for risk stratification for ventric-
ular arrhythmias and SCD. Other important clinical variables
that should be taken into account when assessing overall risk
for VT/VF include patient age, the presence of atrial fibrilla-
tion, symptomatic heart failure and renal failure requiringdialysis, among others. Comorbidities may add incremental
risk.
In some patients with IDCM and recurrent ventricular
arrhythmias, cathetermapping and ablation is indicated. Prior
to entering the laboratory, careful assessment of the surface
ECG morphology of the clinical VT(s) is essential. In our
experience, the surface ECG morphology of a patient’s VT (or
representative VPD) is very helpful for localizing the likely
source and planning the ablation procedure (need to map
right or left ventricles and/or additionally mapping in the
pericardium for epicardial location).45,46 Multiple VT mor-
phologies when identified a priori often predict more exten-
sive distribution of the underlying substrate. We have also
found that in patients with IDCM, VT originating in vicinity of
the LV/RV apex may predict worse LVAD or transplant-free
survival post catheter ablation.47 Additionally, patients pre-
senting clinically with faster ventricular tachycardia rates
may require mechanical hemodynamic support to facilitate
arrhythmia mapping and ablation. In such patients, our
approach comprises substrate modification, which involves
meticulous interpretation of intracardiac signals (electro-
grams) and targeting areas of the scar that manifest specific
abnormal local signal characteristics. Since the presence of
mid-myocardial scar may portend a worse outcome, we
commonly obtain a pre-procedural MRI to assess for late
Fig. 2 e Representative 3-dimensional electroanatomic maps of two patients with IDCM and VT arising from the
interventricular septum. LV bipolar and unipolar voltage is displayed in the right anterior oblique projection. Note that
patients A and B possess septal VT substrate with a large intramural component, as indicated by limited bipolar low voltage
and more extensive areas of unipolar low voltage. Sites of radiofrequency lesions are shown (red markers). LV [ left
ventricle; RAO [ right anterior oblique projection; mV [ millivolt.
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the interventricular septal region refractory to catheter abla-
tion, alcohol ablation has been used. Surgical cryoablation is
the strategy of last resort in patients with incessant VT that
cannot be successfully targeted by a percutaneous
approach.48 Lastly, the use of post-procedural non-invasive
programmed stimulation can be helpful in some cases for
assessing risk of recurrence, antiarrhythmic drug efficacy and
the need for repeat ablation.493. Hypertrophic cardiomyopathy (HCM)
3.1. Background
HCM is a genetically determined disorder of the heart muscle,
most frequently associated with mutations of the sarcomere.
Clinically, HCM is characterized by pathologic left ventricular
hypertrophy, which can lead to a variety of dynamic
obstructive patterns (i.e. septal/outflow tract, mid-cavity,
apical, etc.). The estimated prevalence of HCM is about 1:500
adults (0.2%).50e52 While many patients with HCM have
normal life expectancy, there are subsets of patients with
unfavorable phenotypes (e.g. LV apical aneurysm) yielding an
estimated total annual mortality risk of 0.5e1%.53,54 SCD has
been reported to occur in up to 5% of these patients.55 Non-
sustained ventricular arrhythmias are common and confer
an increased risk of SCD.53,56 Sustained monomorphic VT isless frequent and apical HCM variants may be particularly at
high risk.57,58 The mainstay of treatment for the prevention of
SCD in those deemed at high risk is ICD therapy. In one large
study of 506 adult patients monitored for 2.8 years, rates of
appropriate ICD therapywere 10.6%/yearwhen the devicewas
placed for secondary prevention and 3.6%/year in those
receiving it for primary prevention.59 The overall prevalence
of appropriate ICD interventions in this studywas 20%with an
annual rate of 5.5%. These observations have been replicated
in other smaller series.603.2. Anatomic and electrophysiologic substrate
Histopathologic hallmarks of HCM include myocyte hyper-
trophy with regions of myocyte disarray, variable fibrosis and
small-vessel disease.61e63 Disorganization of the gap junc-
tions has been found, with dispersion of intercellular proteins
around the myocytes leading to altered electromechanical
coupling and ultimately, ventricular arrhythmias. There is
alsomarked increase in interstitial collagen leading to areas of
dense scarring, often worse in the septum compared to the
free wall.64 These structural abnormalities are not apparent
on echocardiography but may be seen by CMRI, which has
become a useful adjunctive imaging modality for this condi-
tion. Delayed enhancement abnormalities (DEA) on CMRI can
be seen in 40e80% of these patients and when present, DEA
are often patchy, mid-myocardial and multifocal (Fig. 3).65
Confluent areas of septal scarring have also been observed
Table 1 e Risk stratification techniques, clinical considerations and markers for SCD in patients with idiopathic dilated,





a. Prior cardiac arrest
b. Family history of SCD
c. Unexplained syncope
d. Holter/event monitor: spontaneous NSVT/VT
e. Stress testing/6 min walk: poor functional capacity, abnormal heart rate recovery
f. Comorbid conditions
2) Myocardial substrate abnormalities/Non-invasive imaging
a. Sinus rhythm ECG: prolonged QRS duration, QRS notching/fragmentation,
epsilon-equivalents
b. Abnormal SAECG
c. TTE: reduced LVEF, increased LV end-diastolic diameter, ventricular dyssynchrony
d. CMRI e delayed gadolinium enhancement
e. EP Study e inducible ventricular arrhythmias; extensive low voltage/abnormal signals on
electroanatomic mapping (apical extension); large mid-epicardial scar burden, multiple
VT morphologies, hemodynamically intolerable VT, recurrent VT at post-ablation non-invasive
programmed stimulation
3) Repolarization abnormalities




a. Reduced short and long-term heart rate variability





a. Prior cardiac arrest
b. Family history of SCD
c. Holter/event monitor: spontaneous VT, high NSVT burden
d. Unexplained syncope
e. Stress testing: hypotensive blood pressure response
2) Myocardial substrate abnormalities/Non-invasive imaging
a. TTE: severe LVH (septal wall thickness>3 mm); large LV outflow tract dynamic gradient;
apical variant
b. CMRI: delayed gadolinium enhancement
c. EP Study: high DFTs, inducible ventricular arrhythmias; extensive low voltage/abnormal
signals on electroanatomic mapping; large mid-epicardial scar burden, multiple VT
morphologies, hemodynamically intolerable VT





b. 1 family member with SCD
c. Spontaneous NSVT/VT (typically LBBB morphology and superior axis)
d. RBBB morphology VT suggestive of LV involvement
2) Myocardial substrate abnormalities/Non-invasive imaging
a. Sinus ECG: precordial T wave inversions, epsilon waves, delayed terminal QRS
activation (parietal block)
b. TTE: extensive regional RV akinesia, dyskinesia or aneurysms; dilated right ventricular
outflow tract
c. CMRI: reduced RVEF, extensive regional RV akinesia, dyskinesia; microaneurysms,
dyssynchronous RV contraction, increased RVEDV/BSA ratio
d. EP Study: extensive areas of low voltage, biventricular involvement, inducible ventricular
arrhythmias; extensive low voltage/abnormal signals on electroanatomic mapping; large
mid-epicardial scar burden, multiple VT morphologies, hemodynamically intolerable VT
3) Genotype: pathogenic desmosomal mutations
SCD ¼ sudden cardiac death; NSVT ¼ nonsustained ventricular tachycardia; VT ¼ ventricular tachycardia; ECG ¼ electrocardiogram;
SAECG ¼ signal-averaged electrocardiogram; TTE ¼ transthoracic echocardiogram; LV ¼ left ventricle; LVEF ¼ left ventricular ejection fraction;
CMRI ¼ cardiac magnetic resonance imaging; EP ¼ electrophysiologic; LVH ¼ left ventricular hypertrophy; DFT ¼ defibrillation threshold;
RV¼ right ventricle; RVEF¼ right ventricular ejection fraction; RVEDV/BSA¼ right ventricular end-diastolic volume to body surface area ratio; L/
RBBB ¼ left or right bundle branch block.
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Fig. 3 e Cardiac MRI images acquired on a 1.5 T magnet from a patient with predominantly septal HCM who underwent VT
ablation. Top panel: short and long-axis bright blood images demonstrating markedly increased (2.3 cm) septal wall
thickness. Bottom panel: dense areas of mid-myocardial delayed gadolinium enhancement were identified in the septal
region (red arrows) as well as patchy areas of the anterior, inferior and lateral epicardium.
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alence of mid-myocardial scarring. It should also be noted,
that a subset of patients with HCM may develop progressive
LV failure and dilation, and ultimately possess a phenotype
that overlaps with IDCM.
While catheter ablation has been used effectively in IDCM,
ARVC and other substrates, its efficacy in HCM is less well
defined. Not only are the voltage criteria for scar less validated
in HCM, but also successful delivery of radiofrequency lesions
that can reach intra-myocardial scar in the severely thickened
ventricle can be challenging. Schumacher and colleagues
have previously shown a significant reduction in regional
voltage amplitude over the septal region in these patients and
the presence of abnormal local electrograms indicating
substrate abnormalities. Our own experience during mapping
studies in patients with hypertrophied ventricles suggests
that the bipolar voltage cutoff of <1.5 mV (similar to estab-
lished reference criteria in IDCM) is often suitable for defining
abnormal tissue.66 Although the catheter ablation experience
for ventricular arrhythmias in patients with HCM is limited,
its efficacy has been reported as being 78% over a mean follow
up ofw3 years.60
3.3. High-risk features
The notion that individualmissensemutations portend a poor
prognosis has fallen out of favor and specific mutations are
less frequently considered benign or malignant.67 However, it
is possible that constellations of multiple mutations may beassociated with a more adverse phenotype. Clinical charac-
teristics associated with a higher risk of SCD in HCM include
prior SCD, family history of SCD, nonsustained or sustained
VT on ambulatory Holter/event monitoring, unexplained
syncope, hypotensive blood pressure response with exercise
and severe LV hypertrophy with diastolic septal wall thick-
ness >3 mm (Table 1).68,69 DEA on MRI may also be useful for
predicting cardiac death and SCD risk.70 Patients with 1
these risk factors may benefit from prophylactic ICDs. An
important concern in HCM patients receiving ICD therapy is
higher defibrillation thresholds (DFT), which has implications
for the ability of these devices to successfully terminate
sustained ventricular arrhythmias. In our experience, DFT
assessment at the time of the ICD implant can be helpful in
identifying such patients. Lastly, it should be noted that in
patients with HCM, programmed electrical stimulation during
EP study has not borne out as a reliable predictor of SCD.714. Arrhythmogenic right ventricular
cardiomyopathy (ARVC)
4.1. Background
ARVC is a genetically determined heart muscle disorder
characterized by fibrofatty replacement of the ventricular
myocardium.72 While the RV is most commonly affected,
involvement of the LV can also occur.73 The estimated prev-
alence of ARVC is 1:2000e1:5000 and it represents an
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 3 5es 4 5 S41important cause of SCD in young adults, accounting for
approximately 11% of cases overall.74 ARVC is inherited as an
autosomal dominant trait with incomplete penetrance and
nearly 20e30% patients have a family history of ARVC or of
SCD.75,76 Numerous desmosomal mutations have been iden-
tified, with the most common being plakophilin-2 and
desmoglein-2 abnormalities.75
The clinical presentation of ARVC is heterogeneous,
ranging from clinically silent disease to SCD. The diagnosis of
ARVC is made on a constellation of features as per the revised
Task Force criteria, which includes 6 diagnostic categories.72
Ventricular arrhythmias, including VPDs and sustained
monomorphic VT are common and can result in high rates of
appropriate ICD therapy.77,78 Although there are no prospec-
tive randomized clinical trials to address the efficacy of ICD
therapy in these patients, observational studies suggest
favorable outcomes overall and certainly for secondary pre-
vention. In the 2012 focused update of the 2008 ACC/AHA
guidelines, the placement of an ICD for primary prevention in
patients with ARVC and 1 risk factors for SCD is listed as a
Class IIa (Level of evidence C) recommendation.794.2. Anatomic and electrophysiologic substrate
Hearts of patients with ARVC manifest RV dilation, wall
thinning and ventricular microaneurysms. Histopathology
studies have shown that the myocardium is atrophied and
replaced with fibrofatty material, largely affecting the mid-
and epicardial layers.80,81 When the clinical suspicion is high,
CMRI imaging is commonly employed during our workupFig. 4 e Typical 3-dimensional right ventricular electroanatomic
underwent VT ablation. Patient A: limited peri-tricuspid endoca
predicted by the areas of low unipolar voltage. Patient B: preser
markedly slowed conduction are shown (black markers). RV [
AP [ anterior-posterior projection; mV [ millivolt.looking for pathognomonic changes of the myocardium.
These may be best visualized by using T1-weighted imaging
and fast spin-echo MRI combined with fat suppression.82e85
Voltage abnormalities using electroanatomic mapping
have been investigated in patients with ARVC undergoing VT
ablation. Our group has shown that low bipolar voltage areas
tend to localize in vicinity of the tricuspid and pulmonic
valves with variable extension toward but typically sparing
the apex (Fig. 4).86 The burden of scar on the epicardium
typically exceeds that on the endocardium.87e89 Given the
preponderance of epicardial scarring, for successful ablation
of VT circuits in these patients, this aspect of the RV usually
needs to be targeted.87,88,90,91 More recently, we have reported
aberrant transmural activation in sinus rhythm in patients
with ARVC who experience VT events. Our findings suggest
layered or “compartmentalized” transmural activation and
uncoupling of the epicardium from the endocardium.88
Research efforts are ongoing in our laboratory to help
further elucidate the pathophysiologic mechanisms of altered
activation in this disease state.4.3. High-risk features
The optimal strategy for risk stratification in ARVC remains
unclear. Clinically, patientswith extensive disease, one ormore
affected family members with SCD and unexplained syncope
are considered to be at high risk for SCD (Table 1). VT in the
majority of patients with ARVC typically manifests LBBB
morphology with a superior axis. The mechanism underlying
VT in these patients is usually reentry and ablation can bevoltage maps from two patients diagnosed with ARVC who
rdial low voltage and extensive epicardial low voltage
ved endocardium but marked epicardial scar. Areas of
right ventricle; RAO [ right anterior oblique projection;
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) s 3 5es 4 5S42effective therapy, although it may require more than one
attempt to adequately target the circuits from the endocardium
and epicardium. In a subset of patients, VT may arise from the
LV and so can manifest RBBB morphology. Patients with ARVC
who manifest multiple VT morphologies that have a biven-
tricular distribution and/or are hemodynamically not well
tolerated can be challenging to ablate. In these patients during
catheter ablation extensive substrate modification targeting
“fractionated” (low amplitude, multicomponent intracardiac
signals) and “late potentials” (intracardiac signals occurring
after theQRS complex is inscribed)may be necessary for lasting
success. Sequential ablation procedures are sometimes
required to render theVTnoninducibleand rarely, patientsmay
have to undergo surgical epicardial cryoablation. Acute success
rates of catheter ablation in these patients are reported to be in
the50e90%rangebutbeyond3years, limited long-termdataare
available with respect to freedom from VT recurrence.90,925. Conclusion
In summary, SCD is a major health problem worldwide. The
mechanism underlying SCD is frequently ventricular ar-
rhythmias and these are more common in patients with
structural heart disease. NICM is an important and perhaps
globally under-recognized form of structural heart disease
that may be a significant contributor to SCD. The optimal
strategy for risk stratification is yet to be determined in pa-
tientswith NICM, particularly thosewith IDCM, HCMor ARVC.
Nevertheless, a multifaceted and systematic approach
comprising careful analysis of 12-lead ECG, advanced imaging
techniques such as CMRI and invasive electroanatomic map-
ping, can often help delineate and characterize the arrhyth-
mogenic substrate in these three conditions. Since the risk of
SCD in an individual may change with time, serial testing
using one or more of the above modalities may be indicated.
ICD therapy has been shown to be useful for reducing
arrhythmic death in patients with NICM. However, long-term
management of devices in these patients can be challenging
because of the younger population age and related issues.
Catheter ablation is an effective strategy in the management
of frequent, symptomatic VPDs as well as sustained ventric-
ular arrhythmias that are refractory to antiarrhythmic drugs.
VT in patients manifesting large mid-myocardial and epicar-
dial scars can be more challenging to successfully ablate. In
patients with hemodynamically intolerable VT, substrate
based ablation targets and the implementation of mechanical
support devices can at times permit successful VT ablation. In
select cases, a hybrid percutaneous-surgical approachmay be
required. Despite decades of progress, further research is
necessary for refining our ability to risk stratify these patients
in order to minimize SCD in those considered at high risk.
Finally, better tools are needed to identify and target the
arrhythmogenic substrate that underlies ventricular ar-
rhythmias in this unique patient population.Conflicts of interest
All authors have none to declare.r e f e r e n c e s
1. Buxton AE, Calkins H, Callans DJ, et al. American College of C,
American Heart Association Task Force on Clinical Data S.
ACC/AHA/HRS 2006 key data elements and definitions for
electrophysiological studies and procedures: a report of the
american college of cardiology/american heart association
task force on clinical data standards (ACC/AHA/HRS writing
committee to develop data standards on electrophysiology). J
Am Coll Cardiol. 2006;48:2360e2396.
2. Myerburg RJ, Castellanos A. In: Zipes DP, Jalife J, eds. Cardiac
Electrophysiology: From Cell to Bedside. 5th Edition. Philadelphia,
PA: Saunders Elsevier; 2009:797e808.
3. Chugh SS, Kelly KL, Titus JL. Sudden cardiac death with
apparently normal heart. Circulation. 2000;102:649e654.
4. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden
cardiac death: mechanisms of production of fatal arrhythmia
on the basis of data from 157 cases. Am Heart J.
1989;117:151e159.
5. Gang UJ, Jons C, Jorgensen RM, et al. Investigators C. Heart
rhythm at the time of death documented by an implantable
loop recorder. Europace. 2010;12:254e260.
6. Girotra S, Nallamothu BK, Spertus JA, Li Y, Krumholz HM,
Chan PS. American Heart Association Get with the
Guidelines-Resuscitation I. Trends in survival after in-
hospital cardiac arrest. N Engl J Med. 2012;367:1912e1920.
7. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac
death in the united states, 1989 to 1998. Circulation.
2001;104:2158e2163.
8. Deo R, Albert CM. Epidemiology and genetics of sudden
cardiac death. Circulation. 2012;125:620e637.
9. Hua W, Zhang LF, Wu YF, et al. Incidence of sudden cardiac
death in china: analysis of 4 regional populations. J Am Coll
Cardiol. 2009;54:1110e1118.
10. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and
morbidity in patients receiving encainide, flecainide, or
placebo. The cardiac arrhythmia suppression trial. N Engl J
Med. 1991;324:781e788.
11. A comparison of antiarrhythmic-drug therapy with
implantable defibrillators in patients resuscitated from near-
fatal ventricular arrhythmias. The antiarrhythmics versus
implantable defibrillators (AVID) investigators. N Engl J Med.
1997;337:1576e1583.
12. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable
defibrillator study (CIDS): a randomized trial of the
implantable cardioverter defibrillator against amiodarone.
Circulation. 2000;101:1297e1302.
13. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized
comparison of antiarrhythmic drug therapy with implantable
defibrillators in patients resuscitated from cardiac arrest: the
cardiac arrest study Hamburg (CASH). Circulation.
2000;102:748e754.
14. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN,
Hafley G. A randomized study of the prevention of sudden
death in patients with coronary artery disease. Multicenter
unsustained tachycardia trial investigators. N Engl J Med.
1999;341:1882e1890.
15. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic
implantation of a defibrillator in patients with myocardial
infarction and reduced ejection fraction. N Engl J Med.
2002;346:877e883.
16. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an
implantable cardioverter-defibrillator for congestive heart
failure. N Engl J Med. 2005;352:225e237.
17. Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart A,
American College of Cardiology F, Heart Rhythm S. American
Heart Association/American College of Cardiology
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 3 5es 4 5 S43Foundation/Heart Rhythm Society scientific statement on
noninvasive risk stratification techniques for identifying
patients at risk for sudden cardiac death: a scientific
statement from the American heart association council on
clinical cardiology committee on electrocardiography and
arrhythmias and council on epidemiology and prevention.
Circulation. 2008;118:1497e1518.
18. Neilan TG, Coelho-Filho OR, Danik SB, et al. CMR
quantification of myocardial scar provides additive
prognostic information in nonischemic cardiomyopathy.
JACC. Cardiovascular imaging. 2013;6:944e954.
19. Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis
with mortality and sudden cardiac death in patients with
nonischemic dilated cardiomyopathy. JAMA.
2013;309:896e908.
20. American College of Cardiology/American Heart Association
Task Force on Clinical Data S, Buxton AE, Calkins H,
Callans DJ, et al. ACC/AHA/HRS 2006 key data elements and
definitions for electrophysiological studies and procedures: a
report of the American College of Cardiology/American Heart
Association task force on clinical data standards (ACC/AHA/
HRS writing committee to develop data standards on
electrophysiology). Circulation. 2006;114:2534e2570.
21. Felker GM, Thompson RE, Hare JM, et al. Underlying causes
and long-term survival in patients with initially unexplained
cardiomyopathy. N Engl J Med. 2000;342:1077e1084.
22. Olshausen KV, Stienen U, Schwarz F, Kubler W, Meyer J. Long-
term prognostic significance of ventricular arrhythmias in
idiopathic dilated cardiomyopathy. Am J Cardiol.
1988;61:146e151.
23. von Olshausen K, Schafer A, Mehmel HC, Schwarz F, Senges J,
Kubler W. Ventricular arrhythmias in idiopathic dilated
cardiomyopathy. Br Heart J. 1984;51:195e201.
24. Meinertz T, Hofmann T, Kasper W, et al. Significance of
ventricular arrhythmias in idiopathic dilated
cardiomyopathy. Am J Cardiol. 1984;53:902e907.
25. Kadish A, Dyer A, Daubert JP, , et alDefibrillators in Non-
Ischemic Cardiomyopathy Treatment Evaluation I.
Prophylactic defibrillator implantation in patients with
nonischemic dilated cardiomyopathy. N Engl J Med.
2004;350:2151e2158.
26. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone
versus implantable cardioverter-defibrillator: randomized
trial in patients with nonischemic dilated cardiomyopathy
and asymptomatic nonsustained ventricular
tachycardiaeAMIOVIRT. J Am Coll Cardiol. 2003;41:1707e1712.
27. de Leeuw N, Ruiter DJ, Balk AH, de Jonge N, Melchers WJ,
Galama JM. Histopathologic findings in explanted heart tissue
from patients with end-stage idiopathic dilated
cardiomyopathy. Transpl Int. 2001;14:299e306.
28. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated
cardiomyopathy: analysis of 152 necropsy patients. Am J
Cardiol. 1987;60:1340e1355.
29. Unverferth DV, Baker PB, Swift SE, et al. Extent of myocardial
fibrosis and cellular hypertrophy in dilated cardiomyopathy.
Am J Cardiol. 1986;57:816e820.
30. Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ.
Visualisation of presence, location, and transmural extent of
healed q-wave and non-q-wave myocardial infarction. Lancet.
2001;357:21e28.
31. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of
heart failure related to dilated cardiomyopathy and coronary
artery disease using gadolinium-enhanced cardiovascular
magnetic resonance. Circulation. 2003;108:54e59.
32. Gardner PI, Ursell PC, Fenoglio Jr JJ, Wit AL.
Electrophysiologic and anatomic basis for fractionated
electrograms recorded from healed myocardial infarcts.
Circulation. 1985;72:596e611.33. Callans DJ, Ren JF, Michele J, Marchlinski FE, Dillon SM.
Electroanatomic left ventricular mapping in the porcine
model of healed anterior myocardial infarction. Correlation
with intracardiac echocardiography and pathological
analysis. Circulation. 1999;100:1744e1750.
34. Hsia HH, Callans DJ, Marchlinski FE. Characterization of
endocardial electrophysiological substrate in patients with
nonischemic cardiomyopathy and monomorphic ventricular
tachycardia. Circulation. 2003;108:704e710.
35. Hutchinson MD, Gerstenfeld EP, Desjardins B, et al.
Endocardial unipolar voltage mapping to detect epicardial
ventricular tachycardia substrate in patients with
nonischemic left ventricular cardiomyopathy. Circ Arrhythm
Electrophysiol. 2011;4:49e55.
36. Soejima K, Stevenson WG, Sapp JL, Selwyn AP, Couper G,
Epstein LM. Endocardial and epicardial radiofrequency
ablation of ventricular tachycardia associated with dilated
cardiomyopathy: the importance of low-voltage scars. J Am
Coll Cardiol. 2004;43:1834e1842.
37. Dixit S, Narula N, Callans DJ, Marchlinski FE. Electroanatomic
mapping of human heart: epicardial fat can mimic scar. J
Cardiovasc Electrophysiol. 2003;14:1128.
38. Cano O, Hutchinson M, Lin D, et al. Electroanatomic substrate
and ablation outcome for suspected epicardial ventricular
tachycardia in left ventricular nonischemic cardiomyopathy.
J Am Coll Cardiol. 2009;54:799e808.
39. Haqqani HM, Tschabrunn CM, Tzou WS, et al. Isolated septal
substrate for ventricular tachycardia in nonischemic dilated
cardiomyopathy: Incidence, characterization, and
implications. Heart Rhythm. 2011;8:1169e1176.
40. Betensky BP, Kapa S, Garcia F, et al. Characterization of
transseptal activation during septal pacing: criteria for
identification of intramural vt substrate in nonischemic
cardiomyopathy. Circ: Arrhythm Electrophysiol.
2013;6:1123e1130.
41. Tzou WS, Zado ES, Lin D, et al. Sinus rhythm ECG criteria
associated with basal-lateral ventricular tachycardia
substrate in patients with nonischemic cardiomyopathy. J
Cardiovasc Electrophysiol. 2011;22:1351e1358.
42. Betensky BP, Deyell MW, Tzou WS, Zado ES, Marchlinski FE.
Sinus rhythm electrocardiogram identification of basal-
lateral ischemic versus nonischemic substrate in patients
with ventricular tachycardia. J Interv Card Electrophysiol.
2012;35:311e321. discussion 321.
43. Das MK, Zipes DP. Fragmented QRS: a predictor of mortality
and sudden cardiac death. Heart Rhythm. 2009;6:S8e14.
44. Simson MB. Use of signals in the terminal QRS complex to
identify patients with ventricular tachycardia after
myocardial infarction. Circulation. 1981;64:235e242.
45. Valles E, Bazan V, Marchlinski FE. ECG criteria to identify
epicardial ventricular tachycardia in nonischemic
cardiomyopathy. Circ Arrhythm Electrophysiol. 2010;3:63e71.
46. Bazan V, Gerstenfeld EP, Garcia FC, et al. Site-specific twelve-
lead ECG features to identify an epicardial origin for left
ventricular tachycardia in the absence of myocardial
infarction. Heart Rhythm. 2007;4:1403e1410.
47. Frankel DS, Tschabrunn CM, Cooper JM, et al. Apical
ventricular tachycardia morphology in left ventricular
nonischemic cardiomyopathy predicts poor transplant-free
survival. Heart Rhythm. 2013;10:621e626.
48. Anter E, Hutchinson MD, Deo R, et al. Surgical ablation of
refractory ventricular tachycardia in patients with
nonischemic cardiomyopathy. Circ Arrhythm Electrophysiol.
2011;4:494e500.
49. Frankel DS, Mountantonakis SE, Zado ES, et al. Noninvasive
programmed ventricular stimulation early after ventricular
tachycardia ablation to predict risk of late recurrence. J Am
Coll Cardiol. 2012;59:1529e1535.
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) s 3 5es 4 5S4450. MaronBJ, Gardin JM, Flack JM,Gidding SS, Kurosaki TT, BildDE.
Prevalence of hypertrophic cardiomyopathy in a general
populationofyoungadults. Echocardiographic analysis of 4111
subjects in the cardia study. Coronary artery risk development
in (young) adults. Circulation. 1995;92:785e789.
51. Zou Y, Song L, Wang Z, et al. Prevalence of idiopathic
hypertrophic cardiomyopathy in china: a population-based
echocardiographic analysis of 8080 adults. Am J Med.
2004;116:14e18.
52. Hada Y, Sakamoto T, Amano K, et al. Prevalence of
hypertrophic cardiomyopathy in a population of adult
Japanese workers as detected by echocardiographic
screening. Am J Cardiol. 1987;59:183e184.
53. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ.
Spectrum and prognostic significance of arrhythmias on
ambulatory holter electrocardiogram in hypertrophic
cardiomyopathy. J Am Coll Cardiol. 2005;45:697e704.
54. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A,
Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical
course and outcome in an unselected regional population. J
Am Coll Cardiol. 1995;26:1529e1536.
55. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in
reported survival rates in patients with hypertrophic
cardiomyopathy. Heart. 2006;92:785e791.
56. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M,
McKenna WJ. Non-sustained ventricular tachycardia in
hypertrophic cardiomyopathy: an independent marker of
sudden death risk in young patients. J Am Coll Cardiol.
2003;42:873e879.
57. Kobayashi K, Ohata T, Ueda H, Miyamoto K. Recurrent
sustained ventricular tachycardia, hypertrophic
cardiomyopathy, and apical aneurysm: electroanatomic
map-guided surgical ablation and left ventricular restoration.
J Thorac Cardiovasc Surg. 2013;146:983e985.
58. Alfonso F, Frenneaux MP, McKenna WJ. Clinical sustained
uniform ventricular tachycardia in hypertrophic
cardiomyopathy: association with left ventricular apical
aneurysm. Br Heart J. 1989;61:178e181.
59. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-
defibrillators and prevention of sudden cardiac death in
hypertrophic cardiomyopathy. JAMA. 2007;298:405e412.
60. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable
cardioverter-defibrillators for the prevention of sudden death
in patients with hypertrophic cardiomyopathy. N Engl J Med.
2000;342:365e373.
61. Davies MJ. The current status of myocardial disarray in
hypertrophic cardiomyopathy. Br Heart J. 1984;51:361e363.
62. Anderson KR, Sutton MG, Lie JT. Histopathological types of
cardiac fibrosis in myocardial disease. J Pathol.
1979;128:79e85.
63. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural
(“small vessel”) coronary artery disease in hypertrophic
cardiomyopathy. J Am Coll Cardiol. 1986;8:545e557.
64. Hughes SE. The pathology of hypertrophic cardiomyopathy.
Histopathology. 2004;44:412e427.
65. To AC, Dhillon A, Desai MY. Cardiac magnetic resonance in
hypertrophic cardiomyopathy. JACC Cardiovasc Imaging.
2011;4:1123e1137.
66. Park RE, Saghy L, Zado ES, Tschabrunn CM, Marchlinski FE.
Influence of left ventricular hypertrophy on scar
identification during bipolar voltage mapping. J Interv Card
Electrophysiol. 2012;34:45e50.
67. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic
cardiomyopathy after 20 years: clinical perspectives. J Am Coll
Cardiol. 2012;60:705e715.
68. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in
hypertrophic cardiomyopathy: identification of high risk
patients. J Am Coll Cardiol. 2000;36:2212e2218.69. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ.
Magnitude of left ventricular hypertrophy and risk of sudden
death in hypertrophic cardiomyopathy. N Engl J Med.
2000;342:1778e1785.
70. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of
late gadolinium enhancement in clinical outcomes for
hypertrophic cardiomyopathy. JACC. Cardiovascular imaging.
2012;5:370e377.
71. Kuck KH, Kunze KP, Schluter M, Nienaber CA, Costard A.
Programmed electrical stimulation in hypertrophic
cardiomyopathy. Results in patients with and without cardiac
arrest or syncope. European Heart J. 1988;9:177e185.
72. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of
arrhythmogenic right ventricular cardiomyopathy/dysplasia:
proposed modification of the task force criteria. Circulation.
2010;121:1533e1541.
73. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant
arrhythmogenic cardiomyopathy: an under-recognized
clinical entity. J Am Coll Cardiol. 2008;52:2175e2187.
74. Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death
and gross and microscopic observations in a series of 200
cases of sudden death associated with arrhythmogenic right
ventricular cardiomyopathy and/or dysplasia. Circulation.
2003;108:3000e3005.
75. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic
right ventricular cardiomyopathy: a practical guide for
physicians. J Am Coll Cardiol. 2013;61:1945e1948.
76. Nava A, Thiene G, Canciani B, et al. Familial occurrence of
right ventricular dysplasia: a study involving nine families. J
Am Coll Cardiol. 1988;12:1222e1228.
77. Nava A, Bauce B, Basso C, et al. Clinical profile and long-term
follow-up of 37 families with arrhythmogenic right ventricular
cardiomyopathy. J Am Coll Cardiol. 2000;36:2226e2233.
78. Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right
ventricular dysplasia: a United States experience. Circulation.
2005;112:3823e3832.
79. Epstein AE, DiMarco JP, Ellenbogen KA, et al, American
College of Cardiology F, American Heart Association Task
Force on Practice G, Heart Rhythm S. 2012 ACCF/AHA/HRS
focused update incorporated into the ACCF/AHA/HRS 2008
guidelines for device-based therapy of cardiac rhythm
abnormalities: a report of the American College of Cardiology
Foundation/American Heart Association task force on
practice guidelines and the heart rhythm society. Circulation.
2013;127:e283ee352.
80. Corrado D, Basso C, Thiene G, et al. Spectrum of
clinicopathologic manifestations of arrhythmogenic right
ventricular cardiomyopathy/dysplasia: a multicenter study. J
Am Coll Cardiol. 1997;30:1512e1520.
81. Burke AP, Farb A, Tashko G, Virmani R. Arrhythmogenic right
ventricular cardiomyopathy and fatty replacement of the
right ventricular myocardium: are they different diseases?
Circulation. 1998;97:1571e1580.
82. Sen-Chowdhry S, Prasad SK, Syrris P, et al.
Cardiovascular magnetic resonance in arrhythmogenic
right ventricular cardiomyopathy revisited: comparison
with task force criteria and genotype. J Am Coll Cardiol.
2006;48:2132e2140.
83. Tandri H, Saranathan M, Rodriguez ER, et al. Noninvasive
detection of myocardial fibrosis in arrhythmogenic right
ventricular cardiomyopathy using delayed-enhancement
magnetic resonance imaging. J Am Coll Cardiol.
2005;45:98e103.
84. Tandri H, Castillo E, Ferrari VA, et al. Magnetic resonance
imaging of arrhythmogenic right ventricular dysplasia:
sensitivity, specificity, and observer variability of fat
detection versus functional analysis of the right ventricle. J
Am Coll Cardiol. 2006;48:2277e2284.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 3 5es 4 5 S4585. Castillo E, Tandri H, Rodriguez ER, et al. Arrhythmogenic right
ventricular dysplasia: ex vivo and in vivo fat detection with
black-blood MR imaging. Radiology. 2004;232:38e48.
86. Marchlinski FE, Zado E, Dixit S, et al. Electroanatomic
substrate and outcome of catheter ablative therapy for
ventricular tachycardia in setting of right ventricular
cardiomyopathy. Circulation. 2004;110:2293e2298.
87. Garcia FC, Bazan V, Zado ES, Ren JF, Marchlinski FE. Epicardial
substrate and outcome with epicardial ablation of ventricular
tachycardia in arrhythmogenic right ventricular
cardiomyopathy/dysplasia. Circulation. 2009;120:366e375.
88. Haqqani HM, Tschabrunn CM, Betensky BP, et al. Layered
activation of epicardial scar in arrhythmogenic right
ventricular dysplasia: possible substrate for confined
epicardial circuits. Circ Arrhythm Electrophysiol.
2012;5:796e803.89. Polin GM, Haqqani H, Tzou W, et al. Endocardial unipolar
voltage mapping to identify epicardial substrate in
arrhythmogenic right ventricular cardiomyopathy/dysplasia.
Heart Rhythm. 2011;8:76e83.
90. Bai R, Di Biase L, Shivkumar K, et al. Ablation of ventricular
arrhythmias in arrhythmogenic right ventricular dysplasia/
cardiomyopathy: arrhythmia-free survival after endo-
epicardial substrate based mapping and ablation. Circ
Arrhythm Electrophysiol. 2011;4:478e485.
91. Dalal D, Jain R, Tandri H, et al. Long-term efficacy of catheter
ablation of ventricular tachycardia in patients with
arrhythmogenic right ventricular dysplasia/cardiomyopathy.
J Am Coll Cardiol. 2007;50:432e440.
92. Arbelo E, Josephson ME. Ablation of ventricular arrhythmias
in arrhythmogenic right ventricular dysplasia. J Cardiovasc
Electrophysiol. 2010;21:473e486.
